Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lifestyle Delivery Systems Inc. Announces that on November 14th 2017, at the CSE Celebration, LDS was Recognized as a Member of the CSE 25 Index

Lifestyle Delivery Systems
Posted on: 27 Nov 17

VANCOUVER, British Columbia, Nov. 27, 2017 /PRNewswire/ -- Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQB: LDSYF) and (Frankfurt: LD6, WKN: A14XHT) ("LDS" or the "Company") is very pleased to announce that it took part in the CSE25 Index Launch Celebration, held by the Canadian Securities Exchange on November 14, 2017. The Company is very proud to be included into the CSE 25 Index.  

At the event Mr. James Pakulis, President of Lifestyle Delivery Systems Inc., was in attendance to receive the award commemorating LDS's induction into the CSE25 Index. Upon accepting the award, Mr. James Pakulis stated, "It's a privilege to represent Lifestyle Delivery Systems as a recipient of the CSE25 Index. We are truly grateful to receive this award. The Canadian Stock Exchange allows companies like Lifestyle Delivery Systems to grow and expand, and management at the CSE is constantly willing to assist and work with their listed companies to help them reach their corporate goals. This is truly a great honor for us."

About the CSE 25 Index

The CSE25 Index is a subgroup of the CSE Composite Index. The composite index launched in 2015 and includes almost half of the exchange's listed companies and covers over 75% of the trading activity on the exchange. The new index includes the top twenty-five securities by market capitalization contained in the composite index. These companies account for over 50% of the weighting in the larger index and are typically stocks that attract considerable trading volume.

About Lifestyle Delivery Systems Inc.

The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking, but also a new way to accurately meter the dosage and assure the purity of the product. In addition, with the entering into its management services agreements with NHMC, Inc. and CSPA Group, Inc., the Company has begun its direct involvement in the growing of medicinal ingredients for, and the manufacturing of, its products.  From seed to sale, the Company's products and ingredients will be tested for quality and composition throughout the formulation and production processes, resulting in a delivery system that is safe, consistent and effective.

On behalf of the board of directors of Lifestyle Delivery Systems Inc. 
Brad Eckenweiler, CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT: 
investor.relations@lifestyledeliverysystems.com 
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In particular, there is significant regulatory uncertainty with respect to the production and sale of medicinal and recreational marijuana in the United States of America. In particular, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect and is subject to change at any time. In addition, although the State of California has adopted laws permitting the commercial cultivation, extraction and manufacturing of medicinal marijuana, final regulations with respect to the implementation of these laws have yet to be adopted.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 27/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.